Description
Supemtek® is a quadrivalent recombinant influenza vaccine developed by Sanofi Pasteur. It is designed to provide active immunization against influenza caused by two influenza A virus subtypes (H1N1 and H3N2) and two influenza B virus lineages (Victoria and Yamagata). Unlike traditional egg-based vaccines, Supemtek® is produced using recombinant DNA technology in an insect cell line, allowing for an exact genetic match to the World Health Organization (WHO) recommended strains . This method eliminates the risk of egg-adapted mutations, potentially enhancing vaccine effectiveness.
Fact Table |
Formula | Recombinant HA proteins from 4 influenza strains |
License | EMA (EU), 2020 |
Bioavailability | High (intramuscular absorption) |
Legal status | Rx-only |
Chemical Name | Quadrivalent recombinant influenza vaccine (QIVr) |
Elimination half-life | Not applicable (vaccine antigen) |
Dosage (Strength) | 0.5 mL containing 45 µg of HA per strain (180 µg total) |
Pregnancy | Use if clearly needed; consult physician |
Brands | Supemtek |
Protein binding | Not applicable |
PubChem CID | Not assigned |
MedlinePlus | a621048 |
ChEBI | Not listed |
ATC code | J07BX03 |
DrugBank | DB11621 |
KEGG | D10962 |
Routes of administration | Intramuscular injection |
Directions
Supemtek® is administered as a single 0.5 mL intramuscular injection, preferably into the deltoid muscle of the upper arm. It is indicated for adults 18 years of age and older. Annual vaccination is recommended, as influenza virus strains and immunity levels can change each year .
Ingredients
Each 0.5 mL dose of Supemtek® contains:
- 45 micrograms of recombinant hemagglutinin (HA) protein per strain, totaling 180 micrograms for all four strains
- Sodium phosphate monobasic monohydrate
- Sodium phosphate dibasic dodecahydrate
Supemtek® is egg-free, latex-free, and contains no preservatives or antibiotics .
Contraindications
Supemtek® is contraindicated in individuals with:
- Hypersensitivity to the active substances or any of the excipients listed above
- Known allergy to octylphenol ethoxylate, a trace residual from the manufacturing process
Cautions
- Postpone vaccination in individuals with acute febrile illness until recovery
- Immunocompromised individuals may have a diminished immune response
- As with all vaccines, appropriate medical treatment should be available in case of an anaphylactic reaction
- Supemtek® may not provide protection against all circulating influenza strains or in all vaccinated individuals
Side Effects
Very common (may affect more than 1 in 10 people):
- Injection site pain and tenderness
- Muscle and joint pain (in adults 18–49 years of age)
Common (may affect up to 1 in 10 people):
- Redness, swelling, or hardness at the injection site
- Fever (>38°C) (in adults 18–49 years of age)
- Muscle and joint pain (in adults 50 years of age and older)
Uncommon (may affect up to 1 in 100 people):
- Gastrointestinal symptoms (e.g., diarrhea, vomiting)
- Lymphadenopathy (swollen lymph nodes)
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14596